Biomerieux SA
PAR:BIM
Operating Margin
Biomerieux SA
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| FR |
|
Biomerieux SA
PAR:BIM
|
14.2B EUR |
15%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.3B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
182.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
149.8B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.5B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.7B USD |
20%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.8B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.3B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
43.5B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.3B USD |
29%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
275.5B CNY |
34%
|
Biomerieux SA
Glance View
In the world of clinical diagnostics, bioMérieux SA emerges as a formidable player, weaving together a tapestry of innovation, precision, and reliability. Founded in 1963 by Alain Mérieux, the company has its roots deeply embedded in Lyon, France, where a legacy of scientific prowess meets a global vision. bioMérieux specializes in in vitro diagnostics, creating a broad array of products and solutions that essentially serve as the medical community’s early warning systems. Their expertise spans across fields like microbiology, immunoassays, and molecular biology, where they craft diagnostic kits and automated instruments that empower healthcare providers to detect and prevent diseases with remarkable accuracy. By tapping into a robust network of research and development, bioMérieux collaborates with hospitals, laboratories, and public health organizations worldwide to address both routine and critical diagnostic needs. At the heart of bioMérieux’s business is its razor-sharp focus on infectious diseases, a sector that has seen accelerated growth in recent years, particularly with the advent of global health challenges such as the COVID-19 pandemic. The firm generates revenue through the sale of its diagnostic solutions and related services, offering comprehensive testing systems that include reagents and consumables, maintenance contracts, and training for laboratory professionals. Their continuous investment in innovation allows them to expand their product portfolio and tailor solutions to the evolving needs of the healthcare industry. By maintaining a pulse on global health trends and investing in cutting-edge technologies, bioMérieux not only secures its market position but also plays a crucial role in strengthening global public health infrastructure.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biomerieux SA's most recent financial statements, the company has Operating Margin of 15.4%.
You don't have any saved screeners yet